We are developing injectable formulations for patients undergoing radiotherapy as a treatment component for various cancers including lung, colon, prostate, head & neck, and brain cancer, where adverse events related to radiation-induced damage to internal organs are prominent. The incidence and severity of adverse events in lung cancer patients receiving radiotherapy makes this population a target for introducing a medical intervention to reduce the risk of life-threatening radiation pneumonitis. 


  • Over 150,000 lung cancer patients annually in the United States receive radiotherapy1
  • 100% of lung cancer patients receiving radiation will experience some damage to normal lung tissue1 and 13% will have Grade 3 or higher severity (severe cough, oxygen or steroid therapy may be required)2


1Global Cancer Facts & Figures, 3rd Edition


2Marsh et al., Journal of Cancer Therapeutics & Research, 2012 


Print Print | Sitemap
© Biocurity